ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint for Clinical Low Risk Breast Cancer Patients at SABCS 2020
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 11, 2020 โ Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted Read More
Agendia Spotlight Poster at SABCS 2020 Confirms Pre-Operative Utility of MammaPrint and BluePrint
Clinical utility of molecular subtyping and risk of recurrence profiling highlighted in largest-ever data set evaluating genomic testing in neoadjuvant setting First look at full 5-year NBRST trial outcome and survival data illustrate genomic diversity Read More
Results from APHINITY Trial using BluePrint as a Biomarker Assay Presented at SABCS in Poster Spotlight Discussion
Agendia and Roche evaluate BluePrintโs stratification of HER2+ early breast cancer patients treated with adjuvant pertuzumab IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 10, 2020 โ Agendia, Inc., a world leader in precision oncology Read More
Agendia Presents Broad Spectrum of Data from FLEX Study Highlighting Tumor Heterogeneity within Underrepresented or Underserved Patient Populations at SABCS 2020
Agendia shares subgroup analyses from the first of its kind, national FLEX Registry with complete, clinically-annotated full genome expression profiling IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ December 9, 2020 โ Agendia, Inc., a world Read More